| pubmed-article:8649341 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0024660 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0006104 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0014298 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0033382 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0242937 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0596902 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C1510827 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0679932 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:8649341 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:8649341 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8649341 | pubmed:dateCreated | 1996-7-19 | lld:pubmed |
| pubmed-article:8649341 | pubmed:abstractText | The high affinity L-proline transporter (PROT) is a member of the family of Na+ (and Cl-)-dependent plasma membrane transport proteins that comprises transporters for several neurotransmitters, osmolytes, and metabolites. The brain-specific expression of PROT in a subset of putative glutamatergic pathways implies a specialized function for this novel transporter and its presumed natural substrate L-proline in excitatory synaptic transmission. However, definitive studies of the physiological role(s) of high affinity L-proline uptake have been precluded by the lack of specific uptake inhibitors. Here, we report that Leu- and Met-enkephalin and their des-tyrosyl derivatives potently and selectively inhibited high affinity L-proline uptake in rat hippocampal synaptosomes and in PROT-transfected HeLa cells. High concentrations of the opiate receptor antagonist naltrexone did not block the inhibitory actions of these peptides, arguing against an involvement of opioid receptors. Des-tyrosyl-Leu-enkephalin elevated the apparent K(m) of L-proline transport in transfected HeLa cells without altering the V(max). PROT-transfected HeLa cells did not accumulate [3H]Leu-enkephalin above background levels, demonstrating that enkephalins are not substrates for PROT. These findings indicate that enkephalins competitively inhibit mammalian brain PROT through a direct interaction with the transporter protein at or near the L-proline binding site. The high potency and specificity of des-tyrosyl-Leu-enkephalin make this compound a useful tool for elucidating the structure-function properties and physiological role(s) of PROT. | lld:pubmed |
| pubmed-article:8649341 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8649341 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8649341 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8649341 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8649341 | pubmed:issn | 0026-895X | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:MillerJ WJW | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:NadlerJ VJV | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:CohenS MSM | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:DominBB | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:BlakelyR DRD | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:FremeauR... | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:ShafqatSS | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:Velaz-Fairclo... | lld:pubmed |
| pubmed-article:8649341 | pubmed:author | pubmed-author:HenziV AVA | lld:pubmed |
| pubmed-article:8649341 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8649341 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:8649341 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8649341 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8649341 | pubmed:pagination | 1033-41 | lld:pubmed |
| pubmed-article:8649341 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:meshHeading | pubmed-meshheading:8649341-... | lld:pubmed |
| pubmed-article:8649341 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8649341 | pubmed:articleTitle | A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter. | lld:pubmed |
| pubmed-article:8649341 | pubmed:affiliation | Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, USA. rtf@galactose.mc.duke.edu | lld:pubmed |
| pubmed-article:8649341 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8649341 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8649341 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8649341 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8649341 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8649341 | lld:pubmed |
